MEDIA & PRESS UPDATES

What's New

Male Scientist
Prize Badge

NEW STARTUP CHANGING THE GAME
Medilabo RFP Wins Globis New Business Plan Contest in 2019

November 15, 2019

Learn More
Chemistry Class

MEDILABO RFP AWARDED 2022 “Industry-Academia-Public Forest” Promotion Project for a full-scale business development 

August 1, 2022

Learn More

Featured

Medilabo RFP's finding of rifampicin attenuates C9orf72-linked dementia was featured in a News medical (May 23, 2022)

Antibiotic rifampicin attenuates C9orf72-linked dementia in genetically modified mice

Excellent efficacy of Medilabo RFP's nasal rifampicin and resveratrol combination in neurodegenerative dementia was introduced in Science Daily (Dec 19, 2021)

Stopping dementia at the nose with combination of rifampicin and resveratrol

Medilabo RFP Awarded 2021 "Industry-Academia-Public Forest" promotion project for business facilitation (Oct 1, 2020)

Development of dementia preventive drug with increased development success rate

Medilabo RFP's CSO, Dr. Tomiyama was featured in Daily Sincho (Mar 23, 2019)

Osaka City University professor explains the mechanism of dramatic effects of existing drugs in "preventing Alzheimer's disease"